Updated
Korsana BiosciencesKRSA · Healthcare
$31.05+2.04%
Market cap$132M
IndustryBiotechnology
Korsana Biosciences (KRSA) Financial statements
Korsana Biosciences reported revenue of $2M in fiscal 2025, down 12.1% a year over 6 years.
Key figures
Net income was -$4M. The diluted share count fell 95% over the period (buybacks).
- Revenue, FY2025
- $2M+3.7% on 2024
- Net income
- -$4M+15.4% on 2024
- Operating margin
- -239.8%
- Free cash flow
- —
Revenue and free cash flow
Fiscal years, from Korsana Biosciences's 10-K filings.
Korsana Biosciences revenue and free cash flow
FY2018–FY2025KRSARevenue$2MKRSAFree cash flow-$41M
Margins
How much of each dollar of revenue is left after the cost of sales, after operating costs, and at the bottom line.
Korsana Biosciences margins
FY2018–FY2025KRSAOperating margin-240%KRSANet margin-170%
Financial statements
Fiscal 2018–2025.
Korsana Biosciences income statement, fiscal 2018–2025
| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $5M | $2M | $4M | $297,000 | $0 | $2M | $2M |
| Research and development | $88M | $95M | $56M | $38M | $6M | $2M | $286,000 | $959,000 |
| Selling, general and admin | $28M | $34M | $29M | $21M | $13M | $8M | $5M | $6M |
| Operating income | -$115M | -$125M | -$81M | -$55M | -$19M | -$13M | -$4M | -$5M |
| Pre-tax income | -$115M | -$122M | -$122M | -$52M | -$44M | -$5M | -$3M | -$4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$115M | -$123M | -$78M | -$52M | -$44M | -$5M | -$3M | -$4M |
| EPS (diluted) | -$1.68 | -$1.80 | -$1.02 | -$0.53 | -$20.28 | -$2.25 | -$1.21 | -$1.11 |
| Diluted shares | 68M | 68M | 76M | 98M | 2M | 2M | 3M | 3M |
| Operating margin | — | -2774.3% | -3539.4% | -1400.2% | -6242.4% | — | -181.4% | -239.8% |
| Net margin | — | -2729.3% | -3388.6% | -1310.2% | -14841.1% | — | -152.8% | -170.1% |
Korsana Biosciences balance sheet, fiscal 2018–2025
| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $0 | $95M | $54M | $54M | $13M | $8M | $3M | $154M |
| Receivables | — | — | $0 | $100,000 | $96,000 | $0 | $556,000 | $1M |
| Total current assets | $879,000 | $101M | $59M | $55M | $15M | $8M | $4M | $155M |
| Property, plant and equipment | $6M | $12M | $7M | $65,000 | $0 | $0 | $0 | $0 |
| Total assets | $7M | $186M | $115M | $59M | $18M | $13M | $10M | $155M |
| Total current liabilities | $18M | $18M | $17M | $11M | $8M | $2M | $725,000 | $12M |
| Long-term debt | $0 | $0 | — | — | — | $0 | $0 | $0 |
| Total liabilities | $18M | $89M | $56M | $11M | $8M | $2M | $725,000 | $13M |
| Shareholders' equity | -$10M | $98M | $59M | $48M | $10M | $11M | $9M | -$34M |
| Net debt | $0 | -$95M | -$51M | -$54M | -$10M | -$8M | -$3M | -$154M |
Korsana Biosciences cash flow, fiscal 2018–2025
| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$98M | -$102M | -$72M | -$37M | -$41M | -$21M | -$4M | -$3M |
| Capital spending | $3M | $7M | $2M | $7,000 | $0 | — | — | — |
| Free cash flow | -$101M | -$109M | -$74M | -$37M | -$41M | — | — | — |
| Stock-based compensation | $12M | $20M | $15M | $10M | $6M | $1M | $625,000 | $441,000 |
| Free cash flow margin | — | -2420.7% | -3223.6% | -926.5% | -13673.7% | — | — | — |
How Korsana Biosciences compares
Korsana Biosciences's revenue growth is higher than 33% of Healthcare companies and 32% of the 3,491 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 33% | 32% |
| ROE | 50% | 18% |
| P/E | 2% | 1% |
Questions about Korsana Biosciences
What was Korsana Biosciences's revenue in 2025?
$2M in fiscal 2025, from its 10-K filing.
From Korsana Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.